J Biol Chem, Vol. 275, Issue 7, 4687-4692, February 18, 2000
Molecular Aspects of Complement-mediated Bacterial Killing
PERIPLASMIC CONVERSION OF C9 FROM A PROTOXIN TO A TOXIN*
Yunxia
Wang
,
Edward S.
Bjes, and
Alfred F.
Esser§
From the Division of Cell Biology and Biophysics, School of
Biological Sciences, University of Missouri-Kansas City,
Kansas City, Missouri 64110
 |
ABSTRACT |
As part of the membrane attack complex complement
protein C9 is responsible for direct killing of bacteria. Here we show
that in the periplasmic space of an Escherichia coli cell
C9 is converted from a protoxin to a toxin by periplasmic conditions
missing in spheroplasts. This conversion is independent of the pathway
by which C9 enters the periplasm. Both, C9 shocked into the periplasm and plasmid-expressed C9 targeted to the periplasm via a
signal sequence are toxic. Toxicity requires disulfide-linked C9
because export into the periplasm of cells defective in disulfide bond synthesis (dsbA and dsbB mutants) is not toxic
unless N-acetylcysteine is added externally to promote
cystines. A N-terminal fragment, C9[1-144], is not toxic nor is
cytoplasmically expressed C9, even in trxB mutants that are
able to form disulfide bonds in the cytoplasm. Importantly, expression
of full-length C9 in complement-resistant cells has no effect on their
viability. Expression and translocation into the periplasm may provide
a novel model to identify molecular mechanisms of other bactericidal
disulfide-linked proteins and to investigate the nature of bacterial
complement resistance.
 |
INTRODUCTION |
Complement is part of the innate immune system and one of the
first lines of defense against pathogenic microorganisms. More than 20 blood complement proteins control microbial invasion of the host by two
different mechanisms: (i) C3-mediated opsonization of cells and (ii)
direct killing as a result of C5b-9 complex formation on the target
(1). Much is known about the strategies used by pathogens to avoid
opsonization because the basic molecular details of the process are
recognized (1-3). In contrast, the mechanisms of direct
complement-mediated killing of Gram-negative bacteria have remained
elusive, and the means used by bacteria to become resistant to its
effects are largely unknown (4). Without doubt, opsonization is of
great importance in many infectious diseases. However, epidemiological
studies of complement-resistant bacteria in systemic infections, as
well as studies on individuals with genetically determined complement
deficiencies, have indicated that (C5b-9)-mediated mechanisms play an
important role in the control of Gram-negative infections. Most
striking is the observation by Lassiter et al. (5) that
Escherichia coli strains that are normally killed by adult
serum ("serum-sensitive" strains) pose a severe threat to survival
of premature or newborn infants because of diminished serum C9
concentrations in neonates.
Microbes escape complement destruction by inhibiting the three pathways
of activation by synthesizing surface proteins that mimic complement
control proteins or by capturing such proteins (1, 3, 4). Resistance to
the action of C5b-9, also referred to as the membrane attack complex
(MAC),1 is frequently
achieved by changes from a rough to a smooth phenotype. Extension of
surface carbohydrate structures causes an increase in the envelope
hydrophilicity and weakens the anchoring of the MAC. Some strains
escape killing by shedding of the MAC. Nevertheless, it is also known
that not all smooth strains are serum-resistant and that some resistant
strains do not shed the MAC but carry it in a stably bound form. Thus,
strains that are truly resistant to complement, in that they are able
to replicate in 50% serum (4), have acquired virulence factors in
addition to those that change the chemical nature of the OM.
Some molecular details of the processes by which the MAC, once
assembled on a bacterium, elicits death are currently understood. Death
of sensitive strains following exposure to serum is extremely rapid,
and it is thought to occur by dissipation of cellular energy (4, 6, 7).
Killing can be prevented by incubation with membrane potential
uncouplers or with inhibitors of oxidative phosphorylation indicating
that ATP generated by the target bacterial cell is required. Efficient
killing requires stable deposition of the C5b-9 complex on the OM but
no other serum components in addition to the terminal complement
proteins. Furthermore, it has been shown that formation of poly(C9), a
tubular polymerization product of C9, is only incidental to hemolysis
and not required for bacterial killing (7-9). However, whereas the
(C5b-8)1C91 complex is sufficient to lyse
erythrocytes fully, it has no bactericidal activity (10). This
observation has been extended to show that a
(C5b-8)1C94 complex is strongly bactericidal
but that incorporation of additional C9 molecules to form poly(C9) does
not improve killing significantly (11). A further important conceptual
advance was provided by Tomlinson et al. (12), who
demonstrated that transfer of preassembled C5b-9 complexes
into the OM by fusion techniques did not elicit cell killing despite
the fact that small molecules now had access to the periplasm. Finally,
Dankert and Esser (7) showed that the C-terminal half of C9, the C9b
fragment, dissipated the membrane potential across respiring inner
membrane (IM) vesicles, although the complete molecule had no effect.
In addition, the requirement for a C9 receptor (that is, C5b-8
assembly) on the OM could be bypassed if the C9 molecule was
osmotically shocked into the periplasmic space (13). This report firmly
established that the bactericidal activity of complement is dependent
upon C9 because none of the other terminal proteins when shocked into the periplasm elicited any cytotoxic effects. What is currently not
understood is how C9, after its binding to the C5b-8 complex on the OM,
translocates across the periplasm and dissipates the potential across
the IM, whether bacterial envelope proteins are needed for these
processes, and, most importantly, where the active (bactericidal)
center is located in the C9 molecule. Here we show that periplasmic
conditions in sensitive cells are important for C9-mediated killing and
that the C5b-8 receptor complex plays no role in the final stages of
this process.
 |
EXPERIMENTAL PROCEDURES |
Complement Proteins and Assays--
Complement proteins C8 and
C9 were purified and assayed for hemolytic activity according to
standard procedures (14), and
-thrombin-cleaved C9 (C9n) was
prepared as published (7).
Bacterial Strains and Killing Assays--
All strains used here
are listed in Table I. Serum or
C9-mediated bacterial killing of bacteria was measured as published (13). Viable spheroplasts were prepared by the method of Marvin and
Witholt (22) and assayed for killing as described for whole cells. YW10
and YW13 are the dsb strains FD596 and NLM100, respectively, lysogenized with
DE3 carrying the inducible gene for T7 RNA
polymerase (
lysogenization kit, Novagen, Madison, WI).
Plasmids and Constructs--
The previously characterized
eukaryotic C9 expression vector pSVLHuC9 (23) and a derivative (pYW29)
with two amino acid mutations, L532S and K538R, and a hexahistidine tag
at the C-terminal end were used as the starting plasmids for the
generation of the prokaryotic expression vectors shown in Table
II. The gene for mature C9 was
transferred in two steps into pET12b. First, a SalI restriction site was introduced into pSVLHuC9 at the end of the C9
signal peptide using the "altered sites mutagenesis system" from
Promega (Madison, WI) and then a
SalI(66)-BamHI(495) fragment was excised and
inserted behind the OmpT signal sequence in pET12b to generate pYW49.
Second, a BamHI(495-1703) fragment excised from pSVLHuC9,
containing C9[144-538] was inserted in frame and in the correct
orientation into BamHI-digested pET12b producing pYW50. To
introduce the hexahistidine tag, pYW51 was generated by digesting pYW50
and pYW29 with NsiI and SacI and replacing the
NsiI-SacI fragment in pYW50 with the
NsiI(1307)-SacI(1700) fragment in pYW29. The
secretion plasmid for full-length C9, pYW52, was made by cutting pYW49
with BamHI and inserting a BamHI(495-1703) fragment excised from pSVLHuC9 in frame and in the correct orientation. For the expression of cytoplasmic C9 first a
NdeI(58)-BamHI(495) polymerase chain reaction
fragment starting at the beginning of mature C9 was generated using
pSVLHuC9 as a template. This fragment was inserted into pET12b to
generate pYW53 and then a BamHI(495-1703) fragment from
pSVLHuC9 was inserted in frame and in the correct orientation to
generate pYW54. Because these pET12b-derived plasmids could not be used
for protein expression (see below) various complete C9 genes together
with ribosomal binding sites and signal sequences (if any) were
transferred as XbaI-SacI fragments into pET22b
and pASK75, respectively, to provide better control of transcription. This resulted in the replacement of the pelB and ompA signal peptides in pET22b and pASK75, respectively, with the ompT signal peptide in the
secretion vectors, and neither the intrinsic hexahistidine tag in
pET22b nor the StrepTM tag in pASK75 were fused
to the C9 constructs. All nucleotide changes were verified by
sequencing.
Expression of Recombinant C9 and Toxicity
Assays--
Transformed cells were grown overnight in LB medium
supplemented with the appropriate antibiotic. Fresh cultures (20 ml) in LB or M63 medium (supplemented with amino acids, thiamine at 1 mg/ml, 1 mM MgSO4, 1 mM sodium citrate, and
0.4% glucose as carbon source and the appropriate antibiotic) (16)
were inoculated at 1:100 dilution and incubated at the desired
temperature under constant shaking. After reaching mid-exponential
growth, phase cultures were split in two, and one half was induced with
either 1 mM isopropyl
-D-thiogalactoside or
50 ng/ml anhydrotetracycline depending on the expression vector, and
the other half served as uninduced control. After about 1 h of
induction, strains lacking functional dsbA or dsbB received 5 mM N-acetylcysteine (NaC) to promote disulfide
pairing (24). Viability of all cultures was assayed by removing small
aliquots at predetermined time points and counting colonies on agar
plates prepared with M63 medium supplemented with casamino acids,
glucose, and the appropriate antibiotic and incubation at 37 °C.
Strains lacking functional thioredoxin reductase (trxB) were
cultured and induced as described (19).
Complement-resistant strains (LP1395 and 25922) were transformed with
pYW60, and ampicillin-resistant colonies were picked and cultured.
After induction with anhydrotetracycline (100 ng/ml), cell viability
was assayed by colony counting as described above.
Ligand Blotting--
Published procedures were used to prepare
total cell lysates and periplasmic shock fluids (25, 26) for SDS-PAGE
analysis and blotting. A polyclonal anti-C9 serum adsorbed on
immobilized cell extracts of E. coli BL21(DE3) or a
monoclonal antibody (mAb216) against human C9 was used to detect
recombinant C9 by Western blotting as described previously (23).
Recombinant proteins carrying the hexahistidine tag were also
visualized using the nickel-nitrilotriacetic acid alkaline phosphatase
conjugate detection system (Qiagen, Valencia, CA).
Proteolysis of Spheroplasts--
NLM100 cells were induced for
3 h to express secretable C9 (pYW60) or cytoplasmic C9 (pYW61),
collected by centrifugation and resuspended in Tris-EDTA-sucrose buffer
and lysozyme at about 1 × 109 cells/ml to produce
spheroplasts as described (17). The spheroplasts were then incubated at
37 °C with trypsin (1 µg/ml) for up to 60 min, aliquots were
withdrawn, and proteolysis was stopped by addition of SBTI (5 µg/ml).
The cells were homogenized by sonication and analyzed by SDS-PAGE and
ligand blotting.
Flotation Gradient Centrifugation--
These experiments were
carried out as described by Thom and Randall (25). In brief,
spheroplasts were lysed by three cycles of freeze-thawing and
sonication, and total lysates were centrifuged for 16 h in a
metrizamide gradient (1.27-1.29 g/ml) at 80,000 rpm in a Beckman
TLA120.2 rotor to separate protein aggregates and membranes. Gradient
fractions were analyzed by SDS-PAGE and ligand blotting.
 |
RESULTS |
Effect of C9 on Viability of E. coli Spheroplasts--
We
previously discovered that when C9 was shocked into the periplasm it
killed sensitive E. coli, whereas it had no effect on
respiring IM vesicles in contrast to the C9b fragment (7, 13). This
prompted us to ask whether periplasmic processing was required for
cytotoxicity. As shown in Fig. 1, neither
native C9 nor C9 cleaved with thrombin (to produce C9a and C9b) had a significant effect on spheroplast viability. This strongly suggested that periplasmic factors are required for toxicity and indicated that
proteolytic cleavage alone is inadequate to convert C9 from a protoxin
to a toxin.

View larger version (8K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of C9 and C9n on viability of
spheroplasts. Viable C600 spheroplasts (1 × 104/ml) were incubated with 25 µg/ml purified C9n
(lane a) or C9 (lane b) or bovine serum albumin
(lane c) for 30 min at 37 °C, and viability was assayed
by counting colonies grown overnight at 37 °C on agar plates
prepared with LB medium.
|
|
Expression of Recombinant C9 and Export into the Periplasm Is
Toxic--
To gain further information on required periplasmic
factors, we introduced C9 into the periplasm from the inside
of the cell by secretion of recombinant C9, rather than from the
outside by osmotic shock. The gene for mature C9 was cloned
into the pET12 vector, which provides an OmpT signal peptide for export
of recombinant proteins into the periplasm to generate pYW52. However,
because of promoter leakiness it was impossible to transform cells
efficiently. When very large amounts of pYW52 DNA were used for
transformation, a few colonies could be recovered. Sequencing of the
plasmid isolated from four different colonies indicated that in each
case the C9 gene was inactivated by insertion of bacterial IS elements
(data not shown). Using vectors derived from pET22b or pASK75 that are more tightly controlled (pYW55-pYW61), transformation was possible, and
recombinant cells could be cultured. Expression of C9 caused an
immediate loss of viability of the cells harboring these plasmids (Fig.
2, A and B). A
secreted, N-terminal fragment, C9[1-144], was not toxic, but the
C-terminal fragment C9[145-538] was as toxic as the complete
molecule (Fig. 2C). Significantly, when C9 was cloned into
either vector without any signal peptide (pYW53, pYW54, pYW58, and
pYW61), no toxic effects were observed after induction, and C9
accumulated as soluble and insoluble forms in the cytoplasm that were
hemolytically inactive (data not shown). Of significance is the fact
that expression of secretable C9 in two complement-resistant strains of
E. coli (LP1395 and 29025) from pYW60 had no effect on
viability (data not shown).

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 2.
Growth curves of E. coli
expressing C9 and C9 fragments. A and
B, E. coli BL21(DE3) transformed with pYW60 ( )
(A) or pYW57 ( ) and pYW58 ( ) (B) were
induced (dashed lines) to express periplasmic C9
(closed symbols) or cytoplasmic C9 (open
symbols). C, expression of N-terminal C9[1-144] from
pYW55 ( ) and C-terminal C9[145-538] from pYW56 ( ). At time 0, 1 mM isopropyl -D-thiogalactoside or 50 ng/ml of anhydrotetracycline was added, and the uninduced control
samples (solid lines) received an identical volume of growth
medium. Viability was assayed by counting colonies grown overnight at
37 °C on M63 agar plates. For easier comparison all growth curves
are normalized to the highest cell number in each panel.
|
|
Disulfide Bond Formation Is Required for Toxicity of Exported
C9--
Although these results suggested that C9 was exported into the
periplasm and exhibited its toxic effects in a manner similar to
external C9 shocked into the periplasm, we could not exclude the
possibility that loss of viability was caused by merely expressing a
foreign gene in E. coli. Many gene products are known to
express such general cytopathic effects. To test for this possibility we took advantage of the fact that C9 is a heavily disulfide-linked protein (Fig. 3A), which is
inactive when reduced. Disulfide bond formation in the periplasm of
E. coli is controlled by the dsbA, dsbB, dsbC, dsbD, dsbE, and
dsbG genes (28). The DsbA protein is a protein disulfide
isomerase in the periplasm that introduces cystines into secreted
proteins and thereby becomes reduced. The DsbB protein is an IM protein
that reoxidizes reduced DsbA. In contrast to wild type cells, E. coli mutants with defective dsbA or dsbB
genes harboring pASK75-derived plasmids were not killed by induction of
C9 expression (Fig. 3, B and C), nor were
DE3 lysogenized dsb mutants (YW10-YW13) transformed with
pET22b-derived vectors (Fig. 3D). This lack of cytotoxicity
is probably related to absence of disulfide bond formation in secreted
C9 and, therefore, proper folding of the molecule because when NaC was
added to the culture medium an immediate viability loss was observed.
Importantly, single and double dsb mutants are not
complement-resistant per se because they were killed in a
C9-dependent process by serum (Table I). Cells harboring
plasmids (pYW58 and pYW61) that express C9 in the cytoplasm were not
affected by NaC addition, suggesting that the effect is specific for
periplasmic C9 and was not caused by NaC directly.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Expression of C9 in dsb
mutants and effect of N-acetylcysteine.
A, location of disulfide bonds in human C9 as published by
Lengweiler et al. (27). E. coli dsbA mutant GJ73
transformed with pYW60 ( ) or pYW61 ( ) (B) and
dsbB mutants NLM100, transformed with pYW60 ( )
(C), and YW10 transformed with pYW57 ( ) or pYW58 ( )
(D) were induced at 40 min with either anhydrotetracycline
or isopropyl -D-thiogalactoside to express periplasmic
C9 (closed symbols) or cytoplasmic C9 (open
symbols), and at 0 min NaC was added to promote disulfide bond
formation. Normalized growth curves of uninduced cultures are shown in
solid lines, and curves of induced cultures are in
dashed lines. CFU values were determined as for Fig.
2.
|
|
Localization of Secreted C9--
To provide direct evidence for
the cellular location of the protein expressed from plasmids coding for
exported C9, we performed protease sensitivity assays. In this assay,
the trypsin sensitivity of C9 is assayed in cells that have been
stripped of their outer cell wall (spheroplasts) exposing periplasmic
but not cytoplasmic contents to the protease. Immunoblots (Fig.
4A) specific for C9 or ligand
blots specific for the His6 tag (Fig. 4B) show
almost complete degradation of periplasmic C9 but complete protection of cytoplasmic C9, indicating that >90% of the exported C9 reached the periplasmic compartment. Flotation gradient centrifugation of
spheroplast lysates can provide further evidence for the localization of expressed proteins and their physical state. As shown in Fig. 4
(C and D), C9 secreted by a dsbB
strain (NML100) was mostly located at the bottom of the metrizamide
gradient, providing evidence that it is either aggregated or associated
with another insoluble protein, and the remainder floated to the top of
the gradient, indicating that some of it is membrane-bound. When we
tested periplasmic shock fluids produced from cells expressing secreted
C9 none could be detected (Fig. 5), nor
was C9[145-538] detectable. In contrast, a N-terminal fragment
(C9[1-144]) was detected easily as was cytoplasmic C9.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
Trypsinization and fractionation of
spheroplasts expressing C9. A, NML100 (dsbB)
cells, induced for 3 h at 30 °C to express periplasmic or
cytoplasmic C9, were converted to spheroplasts. A portion was treated
with 1 µg/ml trypsin at 37 °C for the indicated time at which
aliquots were removed and assayed for the accessibility of C9 to the
protease by SDS-PAGE and Western blottinge (A) or by using
the nickel-nitrilotriacetic acid alkaline phosphatase conjugate
detection system (B). The remainder was lysed by freeze
thawing and sonication. Crude lysates were equilibrated with
metrizamide (final density, 1.27 g/ml), placed at the bottom of a
centrifuge tube, and overlaid with a metrizamide solution of 1.29 g/ml
density. After centrifugation the density of each fraction (recovered
from the top) was determined (C) and analyzed by SDS-PAGE
and Western blotting for the presence of C9 (D).
|
|

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 5.
Western blotting of periplasmic C9 and
fragments. Periplasmic shock fluid of BL21(DE3) cells expressing
C9[1-144] (lane 2), signal-sequenceless C9 (lane
3), and full-length C9 (lane 4) were assayed by
SDS-PAGE and Western blotting for the presence of C9. In lane
1 purified, reduced, and carboxymethylated C9 was applied.
Molecular weight markers are shown in lane 5.
|
|
Periplasmic Tol and Ton Proteins Are Not Required for C9
Toxicity--
Our observations that isolated C9 has no effect on
spheroplast viability but is toxic when shocked into the periplasm of
whole cells suggested that periplasmic constituents may be required for
toxicity. This situation is reminiscent of the action of
membrane-active colicins (9), which require either Tol or Ton proteins
for translocation across the cell envelope, insertion into the IM, and
cell killing (29). However, E. coli strains K17A1 and
KP1032, which are defective in TolA or TonB, respectively, were killed by serum complement (Table I), indicating that these proteins are not
involved in the translocation of C9 across the periplasmic space.
Is Cytoplasmic C9 Toxic?--
The fact that accumulation of C9 in
the cytoplasm of wild type cell is not toxic to the host is not
surprising. First, the protein is mostly in inclusion bodies and
second, because it contains 12 disulfide bonds, it is highly unlikely
that many native conformers will be formed under such circumstances.
Recent advances in understanding the genetics of disulfide bond
metabolism in E. coli led to the creation of thioredoxin
reductase mutants (trxB) in which disulfide bond formation
in proteins localized to the cytoplasm takes place (18). When signal
sequenceless C9 was expressed in E. coli AD494, it
accumulated in the cytoplasm, but its production had no effect on
viability (data not shown). Several additional conditions were examined
that are known to promote disulfide bond formation in trxB
cells, such as growing cells in minimal medium and at lower temperatures (e.g. 23 °C or 30 °C) and then holding
them on ice for a few hours after they are grown, but none impaired
cell viability. Another approach to increase disulfide bond formation
in a cytoplasmic protein has been used by Schneider et al.
(19). These investigators co-expressed the chaperons DnaK and DnaJ
together with SPARC, a protein containing seven disulfide bonds, in
trxB cells and demonstrated that 15-20% soluble monomeric
protein with an electrophoretic mobility characteristic of correctly
disulfide-bonded and biologically active SPARC was formed. When
signal sequenceless C9 was expressed in FC1 cells from the pYW58
plasmid together with DnaK/J from the pDnaK/J plasmid, it still had no
effect on viability of such cells (data not shown), suggesting that
cytoplasmically located C9 is not toxic to E. coli cells.
 |
DISCUSSION |
Native complement protein C9 is a soluble glycoprotein devoid of
cellular toxicity; yet when it enters the periplasmic space of an
E. coli cell it is converted from a protoxin to a toxin. This conversion is independent of the pathway by which C9 enters the
periplasm. Both, C9 shocked into the periplasmic space and C9
synthesized by expression from a plasmid and targeted to the periplasm
via a signal sequence are toxic to the host cell. The toxic
effects of plasmid-derived C9 were not caused simply by overexpressing
a foreign gene because expression of C9 localized to the cytoplasm was
not toxic. The lethal effects were also not due to jamming of the
export pathway because of overexpression because the protein remained
nontoxic when it was targeted to the periplasm of cells with impaired
disulfide-bond catalysis (dsb mutants). In such cells the
protein is translocated across the IM and becomes accessible in
spheroplasts to externally added trypsin verifying its periplasmic
location. The protein, however, is not present in a soluble form in the
periplasm but is mostly aggregated, perhaps in so-called periplasmic
inclusion bodies (30). A small percentage of translocated C9 is also
still associated with the membrane. Wunderlich and Glockshuber (24)
have shown that folding of a disulfide-bonded protein in the oxidative
environment of the periplasm in well oxygenated cell cultures is
influenced by addition of a thiol reagent such as NaC. When this
catalyst was added to dsb mutants harboring C9 in their
periplasm, it elicited an immediate loss of cell viability. We
interpret this result to indicate that some cystine formation and
therefore at least partial folding of the translocated C9 is necessary
for toxicity. Because C9-mediated killing of bacteria is thought to
occur by a single or dual hit process (31), the number of
effective molecules is extremely low, and it is not
surprising that NaC is useful in this process because very few C9
molecules need to form disulfide bonds and fold appropriately to evoke
killing. The effectiveness of a few correctly folded C9 molecules is
also demonstrated by the fact that transformation of wild type cells
was not possible with plasmids in which expression is driven by
promoters that are not tightly controlled.
Truncation of C9 indicated that the N-terminal 144 amino acids are not
required for cytotoxicity and a fragment comprised of these residues
accumulated in soluble form in the periplasm. The remainder,
C9[145-538], however, is as toxic as the complete molecule when
targeted to the periplasm. It contains the C9b fragment and, as shown
earlier (7), this fragment by itself is able to de-energize IM vesicles
and to kill spheroplasts (32). Within this fragment are four disulfide
bonds, three in the epidermal growth factor domain located between
Lys487 and Glu518, and one in the so-called
membrane attack complex/perforin region, connecting Cys359
with Cys384. Experiments are planned to test which of these
cystines are required to fold C9 into a conformer that will elicit
killing of dsb mutants with the help of NaC.
When native C9 enters the periplasm from the outside, either by binding
first to its receptor, through a C5b-8 complex on the OM, or by being
shocked into the periplasm, it is converted to a toxin. Experimental
data are currently missing to distinguish whether this conversion
involves only a refolding of the molecule or the interaction with an
intrinsic periplasmic constituent or both. From our previous work (33)
it is known that membrane insertion of C9 is accompanied by the
transient appearance of refolding conformers that can be trapped by C9
sequence-specific anti-peptide antibodies. In the context of
complement-mediated hemolysis, it is assumed that the interaction of C9
with C5b-8 on the erythrocyte membrane triggers these conformational
changes. However, because C9 can kill in the absence of C5b-8 when
shocked into the periplasm such a (C5b-8)-mediated trigger mechanism
cannot be involved here. One possibility is that the molecule is
proteolytically cleaved in the periplasm and a toxic fragment is
liberated that inserts into the IM. The basis for this hypothesis is
that the C9b fragment can dissipate the membrane potential across IM
vesicles, whereas C9n, in which the C9a and C9b fragments are
still noncovalently associated, cannot and that it is not toxic to
spheroplasts (Fig. 1). It is tempting to speculate that a helper factor
in the cell envelope may interact with the C9b portion of C9 and
convert it to a toxin. This hypothesis is consistent with fact that
cytoplasmic C9 is not toxic even when it is produced under conditions
most favorable to formation of disulfide bonds. One would expect that
under such conditions at least as many properly folded C9 molecules are
created in the cytoplasm as are created by NaC in the periplasm of
dsb mutants and that they should be toxic if no other helper
factors were required.
Such a helper-dependent mechanism is similar to the events
that prevail during the killing of E. coli by
membrane-inserting colicins. These colicins have a receptor binding
domain, a translocation domain, and a membrane insertion domain (29).
The requirement for receptor binding can be bypassed by shocking
colicins into the periplasm. The translocation domain interacts in an
energy-dependent manner with either Tol or Ton proteins.
Because of the similar requirement for a membrane potential and the
inhibitory effects of uncouplers for C9-mediated killing, we tested
whether Tol or Ton proteins play a role in C9 killing. However, two
mutants with defective ton or tol genes, which
are refractory to killing by their respective colicins, are sensitive
to C9-mediated killing, indicating that other periplasmic constituents
are necessary. Considering the tendency of native C9 to undergo
disulfide shuffling2 and the
effect of dsb mutations on the activity of expressed C9, it
was conceivable that the DsbA and DsbB proteins themselves are involved
in serum C9 toxicity. However, this is not the case because
dsb mutants were killed even without NaC by serum
complement, that is, when C9 enters the periplasm from the outside. Of
interest in this context is the fact that E. coli strains
that are resistant to serum complement killing are also resistant to
killing by C9 when it is shocked into the periplasm or when it is
overexpressed in the cytoplasm and targeted to the periplasm. Previous
attempts to generate serum complement-resistant mutants from sensitive strains have led to the generation of smooth phenotypes, that is,
capsule producing mutants or mutants with increased LPS densities and/or longer O-saccharide chains (34, 35). However, unlike patient-derived resistant strains such mutants can frequently be killed
by complement when their OM integrity is impaired. In the future it may
be possible to design genetic screens to search for helper factors that
are required for C9 toxicity by using the targeting of C9 to the
periplasm as described here.
 |
ACKNOWLEDGEMENTS |
We thank Laura Tatar for performing some of
the toxicity experiments shown in Table I, F. Baneyx, J. Beckwith,
E. M. Click, F. Dailey, A. Gatenby, and K. Postle for providing
strains and plasmids, and G. Jander, W. Prinz, and J. Stader for
helpful discussions.
 |
FOOTNOTES |
*
This work was supported by University of Missouri Research
Board Grant 1598, by National Institutes of Health Grants AI19478 and
GM53748, and by a Marion Merrell Dow Professorship Endowment (to
A. F. E.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Present address: Dept. of Cell Biology, Neurobiology, and Anatomy,
Medical College of Wisconsin, Milwaukee, WI 53226.
§
To whom correspondence should be addressed. Tel.: 816-235-5316;
Fax: 816-235-1503; E-mail: essera@umkc.edu.
2
V. Rossi and A. F. Esser, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
MAC, membrane attack
complex;
C9n, C9 cleaved with
-thrombin;
IM, inner
membrane;
OM, outer membrane;
NaC, N-acetylcysteine;
PAGE, polyacrylamide gel electrophoresis.
 |
REFERENCES |
| 1.
|
Tomlinson, S.
(1993)
Curr. Opin. Immunol.
5,
83-89[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Carroll, M. C.
(1998)
Annu. Rev. Immunol.
16,
545-568[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Joiner, K. A.
(1988)
Annu. Rev. Microbiol.
42,
201-230[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Taylor, P. W.
(1995)
in
Virulence Mechanisms of Bacterial Pathogens
(Roth, J. A., ed)
, pp. 49-64, ASM Press, Washington, D.C.
|
| 5.
|
Lassiter, H. A.,
Wilson, J. L.,
Feldhoff, R. C.,
Hoffpauir, J. M.,
and Klueber, K. M.
(1994)
Pediatr. Res.
35,
389-396[Medline]
[Order article via Infotrieve]
|
| 6.
|
Taylor, P. W.,
and Kroll, H. P.
(1983)
Infect. Immun.
39,
122-131[Abstract/Free Full Text]
|
| 7.
|
Dankert, J. R.,
and Esser, A. F.
(1986)
Biochemistry
25,
1094-1100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Dankert, J. R.,
and Esser, A. F.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
2128-2132[Abstract/Free Full Text]
|
| 9.
|
Esser, A. F.
(1994)
Toxicology
87,
229-247[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Bhakdi, S.,
Kuller, G.,
Muhly, M.,
Fromm, S.,
Seibert, G.,
and Parrisius, J.
(1987)
Infect. Immun.
55,
206-210[Abstract/Free Full Text]
|
| 11.
|
MacKay, S. L.,
and Dankert, J. R.
(1990)
J. Immunol.
145,
3367-3371[Abstract]
|
| 12.
|
Tomlinson, S.,
Taylor, P. W.,
and Luzio, J. P.
(1990)
Biochemistry
29,
1852-1860[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Dankert, J. R.,
and Esser, A. F.
(1987)
Biochem. J.
244,
393-399[Medline]
[Order article via Infotrieve]
|
| 14.
|
Esser, A. F.,
and Sodetz, J. M.
(1988)
Methods Enzymol.
162,
551-578[Medline]
[Order article via Infotrieve]
|
| 15.
|
Dailey, F. E.,
and Berg, H. C.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
1043-1047[Abstract/Free Full Text]
|
| 16.
|
Bardwell, J. C.,
Lee, J. O.,
Jander, G.,
Martin, N.,
Belin, D.,
and Beckwith, J.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
1038-1042[Abstract/Free Full Text]
|
| 17.
|
Jander, G.,
Martin, N. L.,
and Beckwith, J.
(1994)
EMBO J.
13,
5121-5127[Medline]
[Order article via Infotrieve]
|
| 18.
|
Derman, A. I.,
Prinz, W. A.,
Belin, D.,
and Beckwith, J.
(1993)
Science
262,
1744-1747[Abstract/Free Full Text]
|
| 19.
|
Schneider, E. L.,
Thomas, J. G.,
Bassuk, J. A.,
Sage, E. H.,
and Baneyx, F.
(1997)
Nat. Biotechnol.
15,
581-585[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Levengood-Freyermuth, S. K.,
Click, E. M.,
and Webster, R. E.
(1993)
J. Bacteriol.
175,
222-228[Abstract/Free Full Text]
|
| 21.
|
Jaskula, J. C.,
Letain, T. E.,
Roof, S. K.,
Skare, J. T.,
and Postle, K.
(1994)
J. Bacteriol.
176,
2326-2338[Abstract/Free Full Text]
|
| 22.
|
Marvin, H. J.,
and Witholt, B.
(1987)
Anal. Biochem.
164,
320-330[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Tomlinson, S.,
Wang, Y.,
Ueda, E.,
and Esser, A. F.
(1995)
J. Immunol.
155,
436-444[Abstract]
|
| 24.
|
Wunderlich, M.,
and Glockshuber, R.
(1993)
J. Biol. Chem.
268,
24547-24550[Abstract/Free Full Text]
|
| 25.
|
Thom, J. R.,
and Randall, L. R.
(1988)
J. Bacteriol.
170,
5654-5661[Abstract/Free Full Text]
|
| 26.
|
Martin, J. L.,
Waksman, G.,
Bardwell, J. C.,
Beckwith, J.,
and Kuriyan, J.
(1993)
J. Mol. Biol.
230,
1097-1100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Lengweiler, S.,
Schaller, J.,
and Rickli, E. E.
(1996)
FEBS Lett.
380,
8-12[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Rietsch, A.,
and Beckwith, J.
(1998)
Annu. Rev. Genet.
32,
163-184[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Stroud, R. M.,
Reiling, K.,
Wiener, M.,
and Freymann, D.
(1998)
Curr. Opin. Struct. Biol.
8,
525-533[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Betton, J. M.,
Boscus, D.,
Missiakas, D.,
Raina, S.,
and Hofnung, M.
(1996)
J. Mol. Biol.
262,
140-150[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Wright, S. D.,
and Levine, R. P.
(1981)
J. Immunol.
127,
1146-1151[Abstract]
|
| 32.
|
Gu, X.,
and Dankert, J. R.
(1996)
J. Immunol. Methods
189,
37-45[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Laine, R. O.,
and Esser, A. F.
(1989)
Nature
341,
63-65[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Tee, G. L.,
and Scott, G. K.
(1980)
Infect. Immun.
28,
387-392[Abstract/Free Full Text]
|
| 35.
|
Kubens, B. S.,
and Opferkuch, W.
(1988)
Zentralbl. Bakteriol. Mikrobiol. Hyg. A
270,
52-65
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. Munro, G. Flatau, A. Doye, L. Boyer, O. Oregioni, J.-L. Mege, L. Landraud, and E. Lemichez
Activation and Proteasomal Degradation of Rho GTPases by Cytotoxic Necrotizing Factor-1 Elicit a Controlled Inflammatory Response
J. Biol. Chem.,
August 20, 2004;
279(34):
35849 - 35857.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. B. Achour, M. Chenik, H. Louzir, and K. Dellagi
Identification of a Disulfide Isomerase Protein of Leishmania major as a Putative Virulence Factor
Infect. Immun.,
July 1, 2002;
70(7):
3576 - 3585.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.